Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Neuroendocrine Tumor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(97)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Neuroendocrine Tumor
No biomarker
Neuroendocrine Tumor
surufatinib
Sensitive: A1 - Approval
surufatinib
Sensitive
:
A1
surufatinib
Sensitive: A1 - Approval
surufatinib
Sensitive
:
A1
No biomarker
Neuroendocrine Tumor
No biomarker
Neuroendocrine Tumor
sunitinib
Sensitive: A1 - Approval
sunitinib
Sensitive
:
A1
sunitinib
Sensitive: A1 - Approval
sunitinib
Sensitive
:
A1
No biomarker
Neuroendocrine Tumor
No biomarker
Neuroendocrine Tumor
everolimus
Sensitive: A1 - Approval
everolimus
Sensitive
:
A1
everolimus
Sensitive: A1 - Approval
everolimus
Sensitive
:
A1
No biomarker
Neuroendocrine Tumor
No biomarker
Neuroendocrine Tumor
lanreotide prolonged-release subcutaneous
Sensitive: A1 - Approval
lanreotide prolonged-release subcutaneous
Sensitive
:
A1
lanreotide prolonged-release subcutaneous
Sensitive: A1 - Approval
lanreotide prolonged-release subcutaneous
Sensitive
:
A1
No biomarker
Neuroendocrine Tumor
No biomarker
Neuroendocrine Tumor
sunitinib
Sensitive: A1 - Approval
sunitinib
Sensitive
:
A1
sunitinib
Sensitive: A1 - Approval
sunitinib
Sensitive
:
A1
SSTR positive
Neuroendocrine Tumor
SSTR positive
Neuroendocrine Tumor
lutetium Lu 177 dotatate
Sensitive: A1 - Approval
lutetium Lu 177 dotatate
Sensitive
:
A1
lutetium Lu 177 dotatate
Sensitive: A1 - Approval
lutetium Lu 177 dotatate
Sensitive
:
A1
VHL mutation
Neuroendocrine Tumor
VHL mutation
Neuroendocrine Tumor
belzutifan
Sensitive: A1 - Approval
belzutifan
Sensitive
:
A1
belzutifan
Sensitive: A1 - Approval
belzutifan
Sensitive
:
A1
No biomarker
Neuroendocrine Tumor
No biomarker
Neuroendocrine Tumor
Sensitive: A2 - Guideline
Sensitive
:
A2
Sensitive: A2 - Guideline
Sensitive
:
A2
No biomarker
Neuroendocrine Tumor
No biomarker
Neuroendocrine Tumor
octreotide
Sensitive: A2 - Guideline
octreotide
Sensitive
:
A2
octreotide
Sensitive: A2 - Guideline
octreotide
Sensitive
:
A2
No biomarker
Neuroendocrine Tumor
No biomarker
Neuroendocrine Tumor
temozolomide
Sensitive: A2 - Guideline
temozolomide
Sensitive
:
A2
temozolomide
Sensitive: A2 - Guideline
temozolomide
Sensitive
:
A2
SSTR positive
Neuroendocrine Tumor
SSTR positive
Neuroendocrine Tumor
lanreotide prolonged-release subcutaneous
Sensitive: A2 - Guideline
lanreotide prolonged-release subcutaneous
Sensitive
:
A2
lanreotide prolonged-release subcutaneous
Sensitive: A2 - Guideline
lanreotide prolonged-release subcutaneous
Sensitive
:
A2
SSTR positive
Neuroendocrine Tumor
SSTR positive
Neuroendocrine Tumor
octreotide
Sensitive: A2 - Guideline
octreotide
Sensitive
:
A2
octreotide
Sensitive: A2 - Guideline
octreotide
Sensitive
:
A2
No biomarker
Neuroendocrine Tumor
No biomarker
Neuroendocrine Tumor
Sensitive: A2 - Guideline
Sensitive
:
A2
Sensitive: A2 - Guideline
Sensitive
:
A2
No biomarker
Neuroendocrine Tumor
No biomarker
Neuroendocrine Tumor
carboplatin + etoposide IV
Sensitive: A2 - Guideline
carboplatin + etoposide IV
Sensitive
:
A2
carboplatin + etoposide IV
Sensitive: A2 - Guideline
carboplatin + etoposide IV
Sensitive
:
A2
No biomarker
Neuroendocrine Tumor
No biomarker
Neuroendocrine Tumor
temozolomide + capecitabine
Sensitive: A2 - Guideline
temozolomide + capecitabine
Sensitive
:
A2
temozolomide + capecitabine
Sensitive: A2 - Guideline
temozolomide + capecitabine
Sensitive
:
A2
BRAF V600E
Neuroendocrine Tumor
BRAF V600E
Neuroendocrine Tumor
trametinib + dabrafenib
Sensitive: A2 - Guideline
trametinib + dabrafenib
Sensitive
:
A2
trametinib + dabrafenib
Sensitive: A2 - Guideline
trametinib + dabrafenib
Sensitive
:
A2
MSI-H/dMMR
Neuroendocrine Tumor
MSI-H/dMMR
Neuroendocrine Tumor
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
No biomarker
Neuroendocrine Tumor
No biomarker
Neuroendocrine Tumor
oxaliplatin
Sensitive: A2 - Guideline
oxaliplatin
Sensitive
:
A2
oxaliplatin
Sensitive: A2 - Guideline
oxaliplatin
Sensitive
:
A2
No biomarker
Neuroendocrine Tumor
No biomarker
Neuroendocrine Tumor
dacarbazine
Sensitive: A2 - Guideline
dacarbazine
Sensitive
:
A2
dacarbazine
Sensitive: A2 - Guideline
dacarbazine
Sensitive
:
A2
RET fusion
Neuroendocrine Tumor
RET fusion
Neuroendocrine Tumor
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
No biomarker
Neuroendocrine Tumor
No biomarker
Neuroendocrine Tumor
cisplatin + etoposide IV
Sensitive: A2 - Guideline
cisplatin + etoposide IV
Sensitive
:
A2
cisplatin + etoposide IV
Sensitive: A2 - Guideline
cisplatin + etoposide IV
Sensitive
:
A2
No biomarker
Neuroendocrine Tumor
No biomarker
Neuroendocrine Tumor
5-fluorouracil
Sensitive: A2 - Guideline
5-fluorouracil
Sensitive
:
A2
5-fluorouracil
Sensitive: A2 - Guideline
5-fluorouracil
Sensitive
:
A2
No biomarker
Neuroendocrine Tumor
No biomarker
Neuroendocrine Tumor
capecitabine
Sensitive: A2 - Guideline
capecitabine
Sensitive
:
A2
capecitabine
Sensitive: A2 - Guideline
capecitabine
Sensitive
:
A2
No biomarker
Neuroendocrine Tumor
No biomarker
Neuroendocrine Tumor
nivolumab + ipilimumab
Sensitive: A2 - Guideline
nivolumab + ipilimumab
Sensitive
:
A2
nivolumab + ipilimumab
Sensitive: A2 - Guideline
nivolumab + ipilimumab
Sensitive
:
A2
No biomarker
Neuroendocrine Tumor
No biomarker
Neuroendocrine Tumor
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
No biomarker
Neuroendocrine Tumor
No biomarker
Neuroendocrine Tumor
Sensitive: A2 - Guideline
Sensitive
:
A2
Sensitive: A2 - Guideline
Sensitive
:
A2
No biomarker
Neuroendocrine Tumor
No biomarker
Neuroendocrine Tumor
carboplatin + irinotecan
Sensitive: A2 - Guideline
carboplatin + irinotecan
Sensitive
:
A2
carboplatin + irinotecan
Sensitive: A2 - Guideline
carboplatin + irinotecan
Sensitive
:
A2
No biomarker
Neuroendocrine Tumor
No biomarker
Neuroendocrine Tumor
cisplatin + irinotecan
Sensitive: A2 - Guideline
cisplatin + irinotecan
Sensitive
:
A2
cisplatin + irinotecan
Sensitive: A2 - Guideline
cisplatin + irinotecan
Sensitive
:
A2
No biomarker
Neuroendocrine Tumor
No biomarker
Neuroendocrine Tumor
Sensitive: A2 - Guideline
Sensitive
:
A2
Sensitive: A2 - Guideline
Sensitive
:
A2
No biomarker
Neuroendocrine Tumor
No biomarker
Neuroendocrine Tumor
Sensitive: A2 - Guideline
Sensitive
:
A2
Sensitive: A2 - Guideline
Sensitive
:
A2
TMB-H
Neuroendocrine Tumor
TMB-H
Neuroendocrine Tumor
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
No biomarker
Neuroendocrine Tumor
No biomarker
Neuroendocrine Tumor
Sensitive: A2 - Guideline
Sensitive
:
A2
Sensitive: A2 - Guideline
Sensitive
:
A2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
